We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Meta-analysis - Eltrombopag

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01235988
Recruitment Status : Completed
First Posted : November 8, 2010
Last Update Posted : June 7, 2017
Information provided by (Responsible Party):

Brief Summary:
The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)

Condition or disease Intervention/treatment
Thrombocytopaenia Drug: Eltrombopag Drug: Placebo

Detailed Description:
Meta-analysis of three studies: Bussell 2007 & Bussell 2009 & RAISE (TRA102537).

Study Type : Observational
Actual Enrollment : 1 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: Systematic Review of the Clinical and Cost Effectiveness of Treatments for Idiopathic (Immune) Thrombocytopenic Purpura (ITP): Direct Meta Analysis
Study Start Date : August 2009
Primary Completion Date : October 2009
Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Eltrombopag
U.S. FDA Resources

Group/Cohort Intervention/treatment
Eltrombopag & standard of care Drug: Eltrombopag
Eltrombopag 50mg & standard of care
Standard of care Drug: Placebo
Placebo + standard of care

Primary Outcome Measures :
  1. >=50 Gi/L platelet count to <400 Gi/L [ Time Frame: 43 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Meta-analysis: A systematic review was conducted to obtain all relevant evidence relating to eltrombopag and relevant studies were selected

Inclusion Criteria:

  • Adults with ITP
  • Received a pre-specified treatment
  • Prospective clinical studies with at least 10 patients

Exclusion Criteria:

  • Subjects with ITP due to other causes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01235988

Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01235988     History of Changes
Other Study ID Numbers: 114013
First Posted: November 8, 2010    Key Record Dates
Last Update Posted: June 7, 2017
Last Verified: June 2017

Additional relevant MeSH terms:
Blood Platelet Disorders
Hematologic Diseases